The GeriPal Podcast, a platform known for its insightful discussions on aging and healthcare, recently delved into the burgeoning field of longevity science, exploring the critical question of whether it represents genuine scientific advancement or mere marketing hype. Hosted by Eric Widera and Alex Smith, the episode featured Dr. Mahtab Jafari, a professor of pharmaceutical sciences and director of the UC Irvine Center for Healthspan Sciences, and Dr. John Newman, a geriatrician and geroscientist affiliated with the Buck Institute and UCSF. The conversation highlighted the rapid evolution of aging research, the challenges in translating laboratory findings to human applications, and the growing influence of significant investment in the sector.<\/p>\n
The Genesis of Longevity Research and Shifting Paradigms<\/strong><\/p>\n Dr. Jafari shared her personal journey into longevity science, which began over two decades ago with a focus on extending lifespan in model organisms like fruit flies and mice. She explained that early aging research primarily concentrated on simply making organisms live longer, often at the expense of their quality of life. "We extended the lifespan of C. elegans and nematodes, and they were just not moving," she recalled, illustrating the disconnect between lifespan and healthspan.<\/p>\n This realization has led to a significant paradigm shift, with a growing emphasis on "healthspan"\u2014the period of life spent in good health, free from debilitating diseases and functional decline. The goal now, as articulated by the guests, is not just to live longer, but to live healthier for longer, enabling individuals to maintain independence and pursue fulfilling lives well into their later years.<\/p>\n Dr. Newman’s entry into the field was rooted in his early fascination with the biological basis of aging. His graduate work inadvertently led him to study a gene associated with premature aging syndromes, sparking a profound realization: "aging is biology." This discovery, occurring around the time aging research was gaining momentum, set him on a path to bridge the gap between understanding aging mechanisms and improving the lives of older adults.<\/p>\n The Influence of Big Money and the Rise of Longevity as an Investment Frontier<\/strong><\/p>\n The discussion touched upon the significant influx of capital into longevity research, particularly in recent years. Dr. Jafari pointed to the establishment of entities like Altos Labs, which reportedly began with a substantial $3 billion in funding and has since attracted even more investment, as a prime example of this trend. While such investments signal growing confidence in the field’s potential, they also introduce complexities, especially when research is conducted with a degree of secrecy, as is the case with Altos Labs.<\/p>\n The conversation also alluded to the involvement of prominent tech billionaires, a phenomenon that has amplified both interest and scrutiny in longevity. This surge in investment, while potentially accelerating breakthroughs, also raises questions about the motivations behind certain research directions and the potential for "snake oil" \u2013 unproven or fraudulent longevity claims\u2014to proliferate alongside legitimate scientific endeavors.<\/p>\n Defining Success: The Challenge of Clinical Trials and Surrogate Markers<\/strong><\/p>\n A central theme of the podcast was the difficulty in rigorously evaluating the efficacy of longevity interventions. Dr. Jafari highlighted the impracticality of conducting 50-year clinical trials to directly measure lifespan or healthspan extension in humans. This necessitates the use of "surrogate markers"\u2014intermediate indicators that suggest a positive impact on aging processes.<\/p>\n In laboratory settings, lifespan and various healthspan assays in model organisms like fruit flies provide valuable insights. Dr. Jafari detailed her systematic approach, which involves measuring mortality, lifespan, and then delving into healthspan indicators such as reproduction, locomotion, sleep patterns, and cognitive function. However, she cautioned against directly extrapolating these findings to humans, stating humorously, "if you are a fruit fly, absolutely go for it. But that\u2019s that."<\/p>\n Dr. Newman elaborated on the challenges of designing human clinical trials for aging interventions. The concept of "multimorbidity," where a single intervention could potentially prevent or treat multiple age-related diseases, has emerged as a promising avenue. The Targeting Aging with Metformin (TAME) study, though facing funding hurdles, aimed to test this very hypothesis by evaluating metformin’s effect on a basket of chronic diseases driven by aging.<\/p>\n Intrinsic Capacity: A New Framework for Geriatric Assessment and Intervention<\/strong><\/p>\n The podcast introduced the World Health Organization’s framework of "intrinsic capacity" as a potentially transformative tool in geriatrics and longevity science. Dr. Newman described intrinsic capacity as a quantitative, comprehensive geriatric assessment across five domains: cognitive function, physical function, mobility, psychological health, sensory health, and vitality. This holistic approach aims to provide a detailed picture of an individual’s overall health and their ability to maintain other functional capacities.<\/p>\n The existence of an ICD-11 code for "age-related decline in intrinsic capacity" signifies its growing recognition as a valid diagnostic concept. The hope is that intrinsic capacity can serve as a robust outcome measure for clinical trials, enabling the development and approval of interventions that target the aging process itself. This framework could provide a more nuanced way to evaluate the impact of both pharmacological and non-pharmacological interventions.<\/p>\n Evaluating Interventions: From Lifestyle to Pharmaceuticals<\/strong><\/p>\n The discussion moved to evaluating specific interventions, categorizing them broadly as "very promising," "promising without data," or "snake oil."<\/p>\n